DE602005013372D1 - Kombination aus Itriglumid und PPI zur Behandlung von gastrointestinalen- und assozierten Krankheiten - Google Patents

Kombination aus Itriglumid und PPI zur Behandlung von gastrointestinalen- und assozierten Krankheiten

Info

Publication number
DE602005013372D1
DE602005013372D1 DE602005013372T DE602005013372T DE602005013372D1 DE 602005013372 D1 DE602005013372 D1 DE 602005013372D1 DE 602005013372 T DE602005013372 T DE 602005013372T DE 602005013372 T DE602005013372 T DE 602005013372T DE 602005013372 D1 DE602005013372 D1 DE 602005013372D1
Authority
DE
Germany
Prior art keywords
gastrointestinal
treatment
combination
itriglumide
ppi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005013372T
Other languages
English (en)
Inventor
Lucio Claudio Rovati
Gianfranco Caselli
Amato Massimo Maria D
Antonio Giordani
Francesco Makovec
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rottapharm SpA
Original Assignee
Rottapharm SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rottapharm SpA filed Critical Rottapharm SpA
Publication of DE602005013372D1 publication Critical patent/DE602005013372D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE602005013372T 2005-07-29 2005-07-29 Kombination aus Itriglumid und PPI zur Behandlung von gastrointestinalen- und assozierten Krankheiten Active DE602005013372D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05107042A EP1747800B1 (de) 2005-07-29 2005-07-29 Kombination aus Itriglumid und PPI zur Behandlung von gastrointestinalen- und assozierten Krankheiten

Publications (1)

Publication Number Publication Date
DE602005013372D1 true DE602005013372D1 (de) 2009-04-30

Family

ID=35351644

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005013372T Active DE602005013372D1 (de) 2005-07-29 2005-07-29 Kombination aus Itriglumid und PPI zur Behandlung von gastrointestinalen- und assozierten Krankheiten

Country Status (9)

Country Link
US (2) US7846921B2 (de)
EP (1) EP1747800B1 (de)
JP (1) JP2009502867A (de)
AT (1) ATE425791T1 (de)
AU (1) AU2006274905B2 (de)
CA (1) CA2616941C (de)
DE (1) DE602005013372D1 (de)
ES (1) ES2324354T3 (de)
WO (1) WO2007014872A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010068907A2 (en) * 2008-12-11 2010-06-17 Mefford Scientific, Llc Compositions of proton pump inhibitors and insulin secretagogues, kits and methods of their use to treat diabetes
MX2014007239A (es) * 2011-12-16 2014-08-08 Atopix Therapeutics Ltd Combinacion de un antagonista crth2 y un inhibidor de bomba de proton para el tratamiento de esofagitis eosinofilica.
BR112016011727A2 (pt) 2013-11-22 2017-08-08 CL BioSciences LLC Antagonistas de gastrina para o tratamento e prevenção de osteoporose
EP3137658B1 (de) * 2014-04-30 2022-03-30 Tseng, Yufeng, Jane Verwendung von bekannten verbindungen als d-aminosäureoxidase-inhibitoren

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3247593A (en) * 1991-12-20 1993-07-28 Warner-Lambert Company Therapeutic combinations useful in the treatment of gastroesophageal reflux disease
SE9702000D0 (sv) * 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
MXPA05012463A (es) * 2003-05-27 2006-01-30 Altana Pharma Ag Combinaciones farmaceuticas de un inhibidor de bomba protonica y un compuesto que modifica la motilidad gastrointestinal.

Also Published As

Publication number Publication date
JP2009502867A (ja) 2009-01-29
CA2616941C (en) 2014-01-21
EP1747800A1 (de) 2007-01-31
EP1747800B1 (de) 2009-03-18
US20110045033A1 (en) 2011-02-24
CA2616941A1 (en) 2007-02-08
AU2006274905A1 (en) 2007-02-08
ATE425791T1 (de) 2009-04-15
ES2324354T3 (es) 2009-08-05
WO2007014872A1 (en) 2007-02-08
AU2006274905B2 (en) 2011-08-18
US7846921B2 (en) 2010-12-07
US20080004303A1 (en) 2008-01-03

Similar Documents

Publication Publication Date Title
EA201170624A1 (ru) Изоникотинамидные антагонисты рецепторов орексинов
ATE538650T1 (de) Cannabinoid-rezeptor-antagonisten / inverse agonisten zur behandlung von übergewicht
ATE516286T1 (de) 5-(ä1,3,4üoxadiazol-2-yl)-1h-indazol und 5-(ä1,3, 4üthiadiazol-2-yl)-1h-indazol derivate als sgk- inhibitoren zur behandlung von diabetes
ATE410161T1 (de) 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazol-3- carbonsäureamid-derivate und verwandte verbindungen als bradykinin b1 rezeptor antagonisten zur behandlung von entzündlichen erkrankungen
DE602005007717D1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
DE602007008434D1 (de) Rezeptoren
DE602007009095D1 (de) Tetrahydropyrrolopyrimidindione und ihre verwendung als inhibitoren der humanen neutrophilen elastase
DE602006009968D1 (de) N4-phenyl-chinazolin-4-aminderivate und verwandte verbindungen als inhibitoren der erbb-typ-i-rezeptortyrosinkinase zur behandlung hyperproliferativer krankheiten
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
NZ548954A (en) Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
ATE551059T1 (de) Fasudil in kombination mit bosentan zur behandlung von pulmonaler arterieller hypertonie
ATE540944T1 (de) Pyridylpiperidinorexin-rezeptorantagonisten
ATE550329T1 (de) Heterobicyclische sulfonamidderivate zur behandlung von diabetes
ATE456955T1 (de) Verwendung von cyclodextrin zur behandlung und vorbeugung von entzündlichen bronchialerkrankungen
JO2645B1 (en) Vehicles
ATE512948T1 (de) Biphenyl-sulfonyl- und phenyl-heteroaryl-sulfonyl-modulatoren des histamin-h3-rezeptors zur behandlung von damit verbundenen erkrankungen
NO20071272L (no) Modulatorer av muskarine reseptorer.
MY149855A (en) Benzimidazole derivatives and their use for modulating the gaba? receptor complex
WO2007019234A3 (en) Aminoethane sulfonamide orexin receptor antagonists
ATE484501T1 (de) Als protein-kinase-inhibitoren nutzbare benzimidazole
MX2009003981A (es) Agentes moduladores del receptor de calcio.
MY150098A (en) Benzylpiperazine derivates and their medical use
ATE425791T1 (de) Kombination aus itriglumid und ppi zur behandlung von gastrointestinalen- und assozierten krankheiten
ATE503752T1 (de) Sulfamide alsendothelinrezeptorantagonsiten zur behandlung von herzkreislauferkrankungen
ATE449077T1 (de) Benzimidazolderivate und ihre verwendung zur modulierung des gabaa-rezeptorkomplexes

Legal Events

Date Code Title Description
8364 No opposition during term of opposition